Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF158K1 in HER-2 Expressing Advanced Solid Tumors
NCT05861895Phase 1Recruiting
- Sponsor
- HighField Biopharmaceuticals
- Start
- Dec 2023
- Primary completion
- Jun 2027
- Modality
- Targeted Liposomes
- Countries
- 2
01
Overview
Phase 1, open-label trial of HF158K1 in solid tumor (3 arms), sponsored by HighField Biopharmaceuticals. Primary endpoints: Incidence of Adverse Events, Incidence of dose-limiting toxicities at 21 days and 6 more. Started Dec 2023; status: recruiting.
02
Drugs
HF158K1
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05861895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05861895.